Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Nursing | Oncology | Pharmacy | Urology | Journal

Back to Journal Articles

Lower Prostate Cancer-Specific Death With Anticoagulant Use

Last Updated: August 30, 2012.

 

Aspirin primarily contributes to reduction for localized cancer treated with prostatectomy, radiotherapy

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Anticoagulant therapy, particularly aspirin, is associated with a reduced risk of prostate cancer-specific mortality among men treated with radical prostatectomy or radiotherapy, according to a study published online Aug. 27 in the Journal of Clinical Oncology.

THURSDAY, Aug. 30 (HealthDay News) -- Anticoagulant (AC) therapy, particularly aspirin, is associated with a reduced risk of prostate cancer-specific mortality (PCSM) among men treated with radical prostatectomy (RP) or radiotherapy (RT), according to a study published online Aug. 27 in the Journal of Clinical Oncology.

To examine the correlation between AC use and the risk of PCSM, Kevin S. Choe, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues analyzed data from 5,955 men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database diagnosed with localized adenocarcinoma of the prostate and treated with RP or RT.

The researchers found that 2,175 of the men (37 percent) were receiving ACs (warfarin, clopidogrel, enoxaparin, and/or aspirin). The risk of PCSM was significantly lower in the AC group compared with the non-AC group (3 versus 8 percent at 10 years), as were the risks of disease recurrence and bone metastasis. The reduction in PCSM was most pronounced in patients with high-risk disease (4 versus 19 percent at 10 years). Regardless of treatment modalities (RT or RP), benefit from AC was seen. PCSM reduction was primarily associated with aspirin, with aspirin use independently associated with a lower risk of PCSM on multivariable analysis (adjusted hazard ratio, 0.43; P = 0.02).

"AC therapy, particularly aspirin, was associated with a reduced risk of PCSM in men treated with RT or RP for prostate cancer," the authors write. "The association was most prominent in patients with high-risk disease."

CaPSURE is supported by an unrestricted educational gift from Abbott Laboratories.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Lacunar Stroke Outcomes No Better With Dual Antiplatelets Next: Nutrient Intake Reduces Sperm DNA Damage in Older Men

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.